TY - JOUR
T1 - REO-10
T2 - A phase I study of intravenous reovirus and docetaxel in patients with advanced cancer
AU - Comins, Charles
AU - Spicer, James
AU - Protheroe, Andrew
AU - Roulstone, Victoria
AU - Twigger, Katie
AU - White, Christine M.
AU - Vile, Richard
AU - Melcher, Alan
AU - Coffey, Matt C.
AU - Mettinger, Karl L.
AU - Nuovo, Gerard
AU - Cohn, David E.
AU - Phelps, Mitch
AU - Harrington, Kevin J.
AU - Pandha, Hardev S.
PY - 2010/11/15
Y1 - 2010/11/15
N2 - Purpose: REOLYSIN (Oncolytics Biotech) consists of a wild-type oncolytic reovirus, which has selective cytotoxicity for tumor cells while sparing normal cells. In a phase I study as a single agent, repeated infusions of reovirus were safe with evidence of antitumor activity. Preclinical studies indicate potential for synergy between reovirus and chemotherapeutic agents. A multicenter, phase I dose escalation study was designed to assess the safety of combining reovirus with docetaxel chemotherapy in patients with advanced cancer. Experimental Design: Patients received 75 mg/m2 docetaxel (day 1) and escalating doses of reovirus up to 3 × 1010 TCID 50 (days 1-5) every 3 weeks. Results: Twenty-five patients were enrolled, and 24 patients were exposed to treatment, with 23 completing at least one cycle and 16 suitable for response assessment. Dose-limiting toxicity of grade 4 neutropenia was seen in one patient, but the maximum tolerated dose was not reached. Antitumor activity was seen with one complete response and three partial responses. A disease control rate (combined complete response, partial response, and stable disease) of 88% was observed. Immunohistochemical analysis of reovirus protein expression was observed in posttreatment tumor biopsies from three patients. Conclusion: The combination of reovirus and docetaxel is safe, with evidence of objective disease response, and warrants further evaluation in a phase II study at a recommended schedule of docetaxel (75 mg/m2, three times weekly) and reovirus (3 × 1010 TCID50, days 1-5, every 3 weeks).
AB - Purpose: REOLYSIN (Oncolytics Biotech) consists of a wild-type oncolytic reovirus, which has selective cytotoxicity for tumor cells while sparing normal cells. In a phase I study as a single agent, repeated infusions of reovirus were safe with evidence of antitumor activity. Preclinical studies indicate potential for synergy between reovirus and chemotherapeutic agents. A multicenter, phase I dose escalation study was designed to assess the safety of combining reovirus with docetaxel chemotherapy in patients with advanced cancer. Experimental Design: Patients received 75 mg/m2 docetaxel (day 1) and escalating doses of reovirus up to 3 × 1010 TCID 50 (days 1-5) every 3 weeks. Results: Twenty-five patients were enrolled, and 24 patients were exposed to treatment, with 23 completing at least one cycle and 16 suitable for response assessment. Dose-limiting toxicity of grade 4 neutropenia was seen in one patient, but the maximum tolerated dose was not reached. Antitumor activity was seen with one complete response and three partial responses. A disease control rate (combined complete response, partial response, and stable disease) of 88% was observed. Immunohistochemical analysis of reovirus protein expression was observed in posttreatment tumor biopsies from three patients. Conclusion: The combination of reovirus and docetaxel is safe, with evidence of objective disease response, and warrants further evaluation in a phase II study at a recommended schedule of docetaxel (75 mg/m2, three times weekly) and reovirus (3 × 1010 TCID50, days 1-5, every 3 weeks).
UR - http://www.scopus.com/inward/record.url?scp=78349299472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78349299472&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-10-1233
DO - 10.1158/1078-0432.CCR-10-1233
M3 - Article
C2 - 20926400
AN - SCOPUS:78349299472
SN - 1078-0432
VL - 16
SP - 5564
EP - 5572
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 22
ER -